Neogenomics Inc NEO

$16.02 -0.52 (-3.14%)

Valuation

Market cap
2,140,095,000
Revenue TTM
$727,330,000
Net income TTM
$-108,030,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
-14.85%
Debt to equity
0.00

Trading

Volume
2,217,500
Avg volume
2,030,210
Day's range
$15.67 – $16.50
Shares out
129,389,000
Stochastic %K
18%
Beta
1.87
Analysts
Moderate Buy
Price target
$23.10

Price

Company profile

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in...

Show more

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. In addition, the company offers molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization. The company was founded in 2001 and is headquartered in Fort Myers, Florida.

Industry
Diagnostics & Research
Sector
Healthcare
Phone
239 768 0600
Website
https://www.neogenomics.com
Address
9490 NeoGenomics Way, Fort Myers, United States

Latest news

Stocktwits

EarningsInsider Nov 10, 4:02 PM
https://www.marketbeat.com/earnings/reports/2026-11-10-neo-performance-materials-inc-stock-1/ $NEO Neo Performance Materials Earnings Tran
0 replies
bmwbuzzz Nov 10, 3:47 PM
$NEO Cant have "pathetic" be such a lasting last post!
1 replies
GTA_Terminal Nov 7, 6:30 AM
Dark pool check on $NEO: what traded off the exchanges this session. The stock moved +2.1% on the day, so this wasn't happening in a quiet tape. Look up any stock's options flow and dark pools on the GTA Terminal, free for 7 days: https://globaltradersacademy.com/start-trial?a=stocktwits&sym=NEO&utm_source=stocktwits&utm_medium=social&utm_campaign=trial&utm_content=NEO Read the full article for the full details: https://globaltradersacademy.com/articles/dark-pool-check-neogenomics-neo?utm_source=stocktwits&utm_medium=social
0 replies
Kat_Harington Nov 2, 4:01 PM
$NEO pathetic
0 replies
AnyMonkey Oct 29, 1:07 AM
$NEO up 112% gotta trim if it goes up to 19 -20 but always drops after good earnings
2 replies
ValueVester Oct 29, 12:02 AM
$NEO nice quarter. All financial metrics moving in the right direction. Continued back to back good quarters usually starts/confirms PPS strength. Previous thoughts are this doesn’t get back to $60 per share, and I’m sticking with that thought pattern. $30 - $35 price target.
0 replies
AnyMonkey Oct 28, 9:23 PM
$NEO Beats. Significantly pares losses. Increases guidance. Whats not to like?
0 replies
filecrux Oct 28, 9:18 PM
$NEO Does NeoGenomics' unflagged raise to about $60M in adjusted EBITDA guidance mark a real turn in profit? 🚀 NeoGenomics, a Florida cancer-testing lab worth about $2.31B at $18 a share at 16:19 ET on October 28, 2026, raised its full-year 2026 adjusted EBITDA guidance to about $60M from $56M–$58M 🚀 The new figure is about 5% above the old midpoint, while the company's October 5, 2026 8-K release had said it was reiterating that EBITDA guidance and flagged an increase only for revenue ⚠️ The $60M full-year guide implies about $17.9M of fourth-quarter adjusted EBITDA after $42.1M in the first nine months, below the third quarter's $18.7M but up from about $13.0M in the fourth quarter of 2025 📅 Next: Warren Stone, now President and COO, becomes CEO effective January 4, 2027, when Tony Zook moves to Executive Chairman Source: SEC 8-K, Oct 28 + SEC 8-K, Oct 5
0 replies